Ser445
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser445  -  EEF2K (human)

Site Information
sGDsGyPsEkRGELD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 483529

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 12 ) , [32P] ATP in vitro ( 12 ) , flow cytometry ( 4 ) , immunoprecipitation ( 4 , 13 ) , mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 8 , 9 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , mass spectrometry (in vitro) ( 11 , 12 ) , mutation of modification site ( 4 , 13 ) , phospho-antibody ( 4 , 7 , 13 ) , phosphopeptide mapping ( 12 ) , western blotting ( 4 , 7 , 13 )
Disease tissue studied:
bone cancer ( 13 ) , breast cancer ( 3 , 6 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 18 ) , cervical adenocarcinoma ( 18 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
EEF2K (human) ( 7 )
Kinases, in vitro:
EEF2K (human) ( 11 , 13 )
Treatments:
2-deoxyglucose ( 4 ) , A484954 ( 4 ) , ischemia ( 6 ) , NH125 ( 13 )

Downstream Regulation
Effects of modification on EEF2K:
molecular association, regulation ( 4 , 13 ) , protein degradation ( 13 ) , ubiquitination ( 13 )
Effects of modification on biological processes:
translation, induced ( 13 )
Induce interaction with:
BRD8 (human) ( 13 ) , BTRC (human) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

4

Wang X, et al. (2015) Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity. Biochem J 467, 321-31
25670349   Curated Info

5

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

6

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

7

Moore CE, Regufe da Mota S, Mikolajek H, Proud CG (2014) A Conserved Loop in the Catalytic Domain of Eukaryotic Elongation Factor 2 Kinase Plays a Key Role in Its Substrate Specificity. Mol Cell Biol 34, 2294-2307
24732796   Curated Info

8

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

9

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

10

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

11

Tavares CD, et al. (2012) Calcium/calmodulin stimulates the autophosphorylation of elongation factor 2 kinase on Thr-348 and Ser-500 to regulate its activity and calcium dependence. Biochemistry 51, 2232-45
22329831   Curated Info

12

Pyr Dit Ruys S, et al. (2012) Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase. Biochem J 442, 681-92
22216903   Curated Info

13

Kruiswijk F, et al. (2012) Coupled Activation and Degradation of eEF2K Regulates Protein Synthesis in Response to Genotoxic Stress. Sci Signal 5, ra40
22669845   Curated Info

14

Mulhern D (2011) CST Curation Set: 12704; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: DpSG
Curated Info

15

Mulhern D (2011) CST Curation Set: 12574; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: DpSG
Curated Info

16

Zhou J (2011) CST Curation Set: 12496; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Possemato A (2010) CST Curation Set: 9072; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

18

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

19

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

20

Zhou J (2009) CST Curation Set: 6956; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

21

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info